Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor.
de Jong KP, Hoedemakers RM, Fidler V, Bijzet J, Limburg PC, Peeters PM, de Vries EG, Slooff MJ. de Jong KP, et al. Scand J Gastroenterol. 2004 Nov;39(11):1141-8. doi: 10.1080/00365520410009609. Scand J Gastroenterol. 2004. PMID: 15545174
Intrapatient 16α-[18F]Fluoro-17β-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
van Geel JJL, Moustaquim J, Boers J, Elias SG, Smeets EMM, Knip JJ, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, Stokkel M, Oprea-Lager DE, Menke-van der Houven van Oordt WC, de Vries EGE, Schröder CP; IMPACT-Metastatic Breast Consortium. van Geel JJL, et al. Among authors: de vries ege. J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984. Online ahead of print. J Nucl Med. 2025. PMID: 39848768
Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, Guiot T, de Vries EGE, Schröder CP, Menke-van der Houven van Oordt CW, Maetens M, Majjaj S, Larsimont D, Rothé F, Sotiriou C, Gebhart G. Rediti M, et al. Among authors: de vries ege. Clin Cancer Res. 2025 Jan 6;31(1):110-121. doi: 10.1158/1078-0432.CCR-24-1007. Clin Cancer Res. 2025. PMID: 39470686
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J; TULIP Trial Investigators. Turner N, et al. J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529. Online ahead of print. J Clin Oncol. 2024. PMID: 39442070
Molecular imaging supports the development of multispecific cancer antibodies.
van Winkel CAJ, Pierik FR, Brouwers AH, de Groot DJA, de Vries EGE, Lub-de Hooge MN. van Winkel CAJ, et al. Among authors: de vries ege. Nat Rev Clin Oncol. 2024 Dec;21(12):852-866. doi: 10.1038/s41571-024-00946-3. Epub 2024 Sep 26. Nat Rev Clin Oncol. 2024. PMID: 39327536 Review.
563 results